Palliative Psychiatry: Relief When Recovery Is Uncertain

When years of treatment have not brought recovery, what should good care offer next? For people living with severe psychiatric illness, that question is deeply personal. Another intervention may offer hope, but it can also bring side effects, disruption, and disappointment. Making everyday life more manageable deserves attention alongside efforts to treat the illness.

A new scoping review by Micaela Forte, co-senior authors Sarah Levitt and Daniel Z. Buchman, and colleagues, published in eClinicalMedicine, examines the relationship between palliative psychiatry and assisted dying.¹ Its subject is how the literature understands these approaches, rather than whether a particular treatment works.

While Forte and colleagues focused specifically on the conceptual boundaries between palliative psychiatry and assisted dying, their findings highlight a broader clinical challenge: how to address existential and persistent suffering when curative models fall short. This broader question provides a useful context for examining cannabis and psychedelic medicine. Understanding where these substances might fit begins with separating psychiatric palliation, supportive care during physical illness, and assisted dying.

What Palliative Psychiatry Means

Palliative psychiatry applies palliative care principles to severe and persistent mental illness, emphasizing quality of life and relief of suffering. The word “palliative” therefore describes a care orientation, rather than automatically meaning that someone is approaching death.

Consider a hypothetical person whose psychiatric symptoms remain difficult after multiple treatments. That person may still want help maintaining relationships, managing distress, or participating in activities that give life meaning. A plan built around those priorities can have value even when complete recovery remains uncertain.

This changes the questions asked during care. How much benefit is an intervention providing? What burdens accompany it? Does the patient consider that tradeoff worthwhile? Goals can be revisited as circumstances change, rather than treating a single decision as permanent.

What the Review Found

The researchers mapped scholarly and grey literature, including 50 publications. Across the full body of literature, the authors mapped positions along a spectrum ranging from differentiated to equivalent. Most publications distinguished the approaches, with 15 characterizing palliative psychiatry and assisted dying as separate practices with distinct goals, and 13 proposing palliative psychiatry as an alternative pathway to assisted dying and usual care.

Some publications were assigned to more than one category, so the counts exceed the 50 publications included in the review.

Overall, the review describes a spectrum of relationships, with the vast majority of publications distinguishing the approaches. The authors call for clearer definitions and research into how palliative psychiatry could operate in practice.

What the Findings Can and Cannot Establish

These counts describe publications, not patients, treatment responses, or votes establishing which approach is best. Mapping a debate does not demonstrate that a proposed care pathway improves outcomes.

A practical implication is that the next questions concern implementation. What would patients actually receive? How would their priorities be recorded? How would clinicians determine whether care was helping? These questions require patient experiences and clinical evidence alongside conceptual discussion.

A separate 2026 consensus statement on futility in psychiatry identifies potential benefits from reconsidering burdensome treatments, alongside risks including psychological harm and premature treatment discontinuation. It reinforces why persistent symptoms should not become a casual declaration that further improvement is impossible.

Comfort-focused care needs to remain active care. Otherwise, a language intended to recognize suffering could become a justification for withdrawing attention or resources.

Cannabis in Palliative Care Addresses a Different Population

Cannabis enters this discussion most naturally through supportive care during serious physical illness. Helping a patient with cancer manage treatment-related symptoms is a different clinical question from treating severe and persistent psychiatric illness.

The connection between these settings is the importance of daily experience. A patient may value being comfortable enough to eat, alert enough to speak with family, or sufficiently rested to participate in something meaningful. Those outcomes deserve attention, but a shared goal does not make treatments interchangeable.

In a November 2025 interview about cannabis in palliative care, McGill physician Dr. Claude Cyr discusses patients’ experiences of comfort, connection, and enjoyment. His observations illustrate why clinicians may consider outcomes beyond a symptom checklist. They remain expert perspectives rather than proof of benefit for every patient.

Patient Use Does Not Prove Effectiveness

A 2026 study of cannabis use and symptom burden compared patients with cancer receiving palliative care. Those reporting cannabis use had higher overall symptom scores, including greater pain, anxiety, and depression in unadjusted comparisons.

The findings cannot show whether cannabis caused those symptoms. People experiencing greater suffering may be more likely to seek additional relief. The comparison also cannot establish that cannabis successfully relieved their distress.

This is an important distinction for reporting medical cannabis research. Patient demand identifies a need worth investigating. It does not, by itself, establish which product helps, which symptom improves, or whether benefits outweigh adverse effects.

Match Cannabinoid Evidence to Specific Symptoms

The ASCO guideline on cannabis and cannabinoids in adults with cancer identifies a potential role for certain cannabinoid treatments when chemotherapy-related nausea and vomiting persist despite recommended antiemetic care. Evidence for other supportive uses remains uncertain. The guideline also recommends against cannabis as a cancer-directed treatment outside clinical trials.

That distinction matters. Evidence for one specific symptom cannot support a general claim that cannabis treats cancer, depression, insomnia, pain, and existential distress.

The product matters too. Cannabis preparations differ in THC and CBD content, formulation, and administration route. Findings involving a standardized preparation should not become an endorsement of every product bearing a cannabis label.

MyCannabis’s recent examination of why cannabis research still lags behind the science discusses barriers to stronger evidence. Those obstacles help explain uncertainty, but they cannot establish a benefit that clinical studies have not demonstrated.

For care teams, a useful approach is to connect any proposed intervention to a defined goal and reassess the result. Did the symptom improve? Did unwanted effects interfere with something the patient values? Is continuing the intervention still worthwhile?

Psychedelic Research Offers Questions Worth Testing

Psychedelics provide another connection through research into depression and psychological distress. However, studies involving selected patients with depression or advanced cancer cannot automatically establish suitability for everyone living with severe psychiatric illness.

In its June 2026 overview of psychedelics and mental health research, CAMH describes ongoing investigations while emphasizing that the work remains experimental. Trials use controlled environments and carefully selected participants. People with personal or family histories of psychosis are often excluded because of potential risks.

The National Cancer Institute also lists research investigating psilocybin-assisted psychotherapy for psychiatric and existential distress in advanced cancer. This establishes that researchers are testing the approach, rather than proving that it is effective.

Screening, preparation, supervision, and follow-up form part of the research context. Independently taking a substance does not reproduce that clinical setting.

The most useful future evidence would connect symptom changes with outcomes patients value, including functioning, relationships, and sustained well-being. It would also report harms and identify who may be poorly suited to an intervention.

Assisted Dying Requires a Separate Discussion

As of September 2026, Canada’s medical assistance in dying rules exclude eligibility when mental illness is the sole underlying medical condition until March 17, 2027. Legal eligibility and research into relief of suffering are separate questions.

Neither cannabis nor psychedelics should be presented as a proven means of preventing assisted dying requests. Equally, the existence of experimental treatments should not create an expectation that a suffering person must pursue every imaginable intervention.

When considering emerging treatments, useful questions include:

• Which symptom or personal goal is being addressed?
• How closely does the evidence match this patient?
• What burdens could offset the potential benefit?
• When will the outcome be reassessed?

Quality of Life Deserves Its Own Evidence

The broader lesson is that relief remains a worthwhile goal when recovery is uncertain. Evaluating that relief requires attention to both measurable symptoms and the experiences a patient wants to preserve.

For cannabis and psychedelic medicine, this means moving beyond enthusiasm for a compound. Medicines must be evaluated within a care plan that includes dependable support and respect for individual priorities. Progress should help patients live more comfortably and meaningfully, while keeping uncertainty visible.

References:

¹ Forte, M., Panko, L., Tsiandoulas, K., Rodak, T., Costa, L., Levitt, S., & Buchman, D. Z. (2026). The relationship between palliative psychiatry and assisted dying: A scoping review. eClinicalMedicine, 100, Article 104200. https://doi.org/10.1016/j.eclinm.2026.104200